Literature DB >> 25904835

Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab.

.   

Abstract

Entities:  

Year:  2014        PMID： 25904835      PMCID： PMC4302495     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  5 in total

1.  Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.

Authors:  Yanli Zhuang; Zhenhua Xu; Bart Frederick; Dick E de Vries; Joyce A Ford; Monica Keen; Mittie K Doyle; Kevin J Petty; Hugh M Davis; Honghui Zhou
Journal:  Clin Ther       Date:  2011-12-14       Impact factor: 3.393

Review 2.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

Authors:  Geert D'Haens; William J Sandborn; Brian G Feagan; Karel Geboes; Stephen B Hanauer; E Jan Irvine; Marc Lémann; Philippe Marteau; Paul Rutgeerts; Jurgen Schölmerich; Lloyd R Sutherland
Journal:  Gastroenterology       Date:  2006-12-20       Impact factor: 22.682

3.  Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Authors:  Honghui Zhou; Haishan Jang; Roy M Fleischmann; Esther Bouman-Thio; Zhenhua Xu; Joseph C Marini; Charles Pendley; Qun Jiao; Gopi Shankar; Stanley J Marciniak; Stanley B Cohen; Mahboob U Rahman; Daniel Baker; Mary Ann Mascelli; Hugh M Davis; Daniel E Everitt
Journal:  J Clin Pharmacol       Date:  2007-03       Impact factor: 3.126

4.  Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group.

Authors:  E J Irvine; B Feagan; J Rochon; A Archambault; R N Fedorak; A Groll; D Kinnear; F Saibil; J W McDonald
Journal:  Gastroenterology       Date:  1994-02       Impact factor: 22.682

5.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Brian G Feagan; Colleen Marano; Hongyan Zhang; Richard Strauss; Jewel Johanns; Omoniyi J Adedokun; Cynthia Guzzo; Jean-Frederic Colombel; Walter Reinisch; Peter R Gibson; Judith Collins; Gunnar Järnerot; Toshifumi Hibi; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2013-06-02       Impact factor: 22.682
  5 in total
  2 in total

1.  Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases.

Authors:  Yong Eun Park; Hye Su Moon; Dongeun Yong; Hochan Seo; Jinho Yang; Tae-Seop Shin; Yoon-Keun Kim; Jin Ran Kim; Yoo Na Lee; Young-Ho Kim; Joo Sung Kim; Jae Hee Cheon
Journal:  Sci Rep       Date:  2022-04-15       Impact factor: 4.996

Review 2.  Golimumab (anti-TNF monoclonal antibody): where we stand today.

Authors:  Ana Teresa Melo; Raquel Campanilho-Marques; João Eurico Fonseca
Journal:  Hum Vaccin Immunother       Date:  2020-12-28       Impact factor: 3.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.